Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- CSPC Ouyi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pegylated liposomal doxorubicin (PLD) + ifosfamide is a combination chemotherapy regimen used primarily for the treatment of advanced or metastatic soft tissue sarcomas. PLD is a formulation of doxorubicin encapsulated in liposomes with attached polyethylene glycol (PEG) molecules, which increases circulation time, reduces drug leakage, and enhances tumor targeting while reducing cardiotoxicity. Ifosfamide is an alkylating agent that interferes with DNA replication and transcription of RNA, leading to cell death. The combination leverages the antitumor effects of both agents while potentially offering a more favorable toxicity profile compared to conventional doxorubicin combinations.
- Brand names
- Caelyx + ifosfamideDoxil + ifosfamide
- Other names
- PLD + IFO
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + ifosfamide.